Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients

The FDA has signed off Lipocine Inc’s (NASDAQ:LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate…
byVandana Singh
June 14, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • The FDA has signed off Lipocine Inc’s (NASDAQ:LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression (PPD) in adults.
  • A pharmacokinetic (PK) study to assess dose proportionality is planned to start in July 2021, with top-line results expected in the third quarter of 2021.
  • Following the PK study, a proof-of-concept study to evaluate the safety, tolerability, and efficacy of LPCN 1154 in adult female subjects is expected to start dosing in the fourth quarter of 2021.
  • Price Action: LPCN shares are up 12% at $1.49 during the market session on the last check Monday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AMETEK: Q1 Earnings Insights

By Benzinga Insights
Today, 3:14 AM
  AMETEK (NYSE:AME) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:55 AM. Here's what investors need to know about the announcement. Earnings AMETEK beat estimated earnings by 4.72%, reporting an EPS of $1.33 versus an estimate of $1.27.

AME